Brief Introduction
Dr. Lee has dedicated many years to advancing cell therapy for both hematological malignancies and solid tumors. He currently leads the oncology and cell therapy teams at Taichung Veterans General Hospital, with a strong focus on translating innovative cellular therapies into clinical practice and early-phase clinical trials.
Specialty
- GI and pancreatic cancers, Breast cancer, Lymphoma, Cancer immunotherapy and engineered novel cell therapies (CAR-T, TCR-T, TILs)
Education
- 1996: Ph.D., University of Maryland, School of Medicine, Baltimore, Maryland, U.S.A.
- 1989: M.D., National Yang-Ming University, College of Medicine, Taipei, Taiwan
Experience
- 2022/02 - Present: Director, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan
- 2022/02 - Present: Director, Cell Therapy and Regenerative Medicine Center, Taichung Veterans General Hospital, Taichung, Taiwan
Selected Publications
- Real-world Characteristics and Treatment Patterns in Essential Thrombocythemia: A Population-based Cross-sectional Study in Taiwan between 2020 and 2021. Therapeutic Advances in Hematology 2025 Jun.
- Fan YC, Fong YC, Kuo CT, Li CW, Chen WY, Lin JD, Bürtin F, Linnebacher M, Bui QT, Lee KD, Tsai YC. Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer. Cell Biosci. 2023 Aug 10;13(1):147.